GSK Plans Job Cuts and £1.9bn Savings While Investing £400m in UK Research
GSK plans job cuts and a £1.9 billion cost-reduction programme while committing £400 million to UK life sciences and consolidating research operations around Cambridge and Ware.

British drugmaker GSK announced on Tuesday, July 28, 2026, that it plans job cuts as part of a £1.9 billion cost-reduction programme while investing £400 million in UK life sciences over the next three years.
The company said more than 1,000 scientists will move to a new research and development site at the Cambridge Biomedical Campus. GSK plans to close its Stevenage research site in Hertfordshire by 2029, while upgrading laboratories in nearby Ware and relocating some employees there.
The restructuring is intended to support faster drug development under the company’s new chief executive. GSK did not specify the number of jobs to be eliminated in the source material reviewed by AddisMizan.
The combination of cost reductions, site consolidation and new research spending marks a significant reorganisation of GSK’s UK research footprint. The precise workforce impact will depend on further details from the company as the programme is implemented.



